PharmacoEconomics & Outcomes News 680 - 15 Jun 2013 Oncotype DX assay cost effective in early breast cancer Routine Oncotype DX 21-gene testing is associated with improved QALYs in women with early-stage breast cancer and is cost effective in the setting of the UK NHS, according to a study conducted at a cancer centre in West Wales, UK. The study examined the effect of routine Oncotype DX testing on chemotherapy decisions and assessed the cost effectiveness of the assay, compared with current clinical practice, using a Markov model with a 30-year time horizon. * The study included 146 women with excised, oestrogen-receptor (ER)- positive, node-negative (pN0) or micrometastic (pN1mi) breast cancer who were assessed for adjuvant chemotherapy and offered Oncotype DX testing. Oncotype DX testing resulted in changes in chemotherapy decisions, based on the Recurrence Score result, for 38 of the 142 women who were evaluable for the final analysis. In 26 women, treatment was revised to hormone therapy alone, sparing them from chemotherapy. The model predicted that the use of Oncotype DX testing was associated with a gain of 0.14 QALYs. The cost analysis, performed from a third- party payer perspective, showed an incremental cost of £6232 (2010 value) per QALY gained for Oncotype DX testing, compared with current clinical practice. * The study was supported by funding from Genomic Health International. Holt S, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER- positive breast cancer in the UK. British Journal of Cancer : 21 May 2013. Available from: URL: http://dx.doi.org/10.1038/bjc.2013.207 803087865 1 PharmacoEconomics & Outcomes News 15 Jun 2013 No. 680 1173-5503/10/0680-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Oncotype DX assay cost effective in early breast cancer

Download PDF Report

Upload
lillian-turner
View
212
Download
0

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 680 - 15 Jun 2013

Oncotype DX assay cost effectivein early breast cancer

Routine Oncotype DX 21-gene testing is associatedwith improved QALYs in women with early-stage breastcancer and is cost effective in the setting of the UK NHS,according to a study conducted at a cancer centre inWest Wales, UK.

The study examined the effect of routineOncotype DX testing on chemotherapy decisions andassessed the cost effectiveness of the assay, comparedwith current clinical practice, using a Markov modelwith a 30-year time horizon.* The study included146 women with excised, oestrogen-receptor (ER)-positive, node-negative (pN0) or micrometastic (pN1mi)breast cancer who were assessed for adjuvantchemotherapy and offered Oncotype DX testing.

Oncotype DX testing resulted in changes inchemotherapy decisions, based on the RecurrenceScore result, for 38 of the 142 women who wereevaluable for the final analysis. In 26 women, treatmentwas revised to hormone therapy alone, sparing themfrom chemotherapy. The model predicted that the use ofOncotype DX testing was associated with a gain of0.14 QALYs. The cost analysis, performed from a third-party payer perspective, showed an incremental cost of£6232 (2010 value) per QALY gained for Oncotype DXtesting, compared with current clinical practice.* The study was supported by funding from Genomic HealthInternational.

Holt S, et al. A decision impact, decision conflict and economic assessment ofroutine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. British Journal of Cancer : 21 May 2013.Available from: URL: http://dx.doi.org/10.1038/bjc.2013.207 803087865